Original Article

Performance of Aptima HPV E6/E7 mRNA Test for Detection of Cervical Lesions in a Large Chinese Population

Abstract

Background: We aimed to examine the effectiveness of Aptima HPV E6/E7 mRNA test for detection of cervical lesions in a large Chinese population.

Methods: Overall, 4,350 women, who received simultaneously Aptima HPV E6/E7 mRNA test and HPV DNA test, followed by cervical biopsy in the Department of Gynecology of the Second Affiliated Hospital of Soochow University, Jiangsu Province, China from 2016-2020, were recruited. The detection of cervical lesions was compared between Aptima HPV E6/E7 mRNA test and HPV DNA test.

Results: Overall, HPV DNA test exhibited a higher detection of all cervical lesions than Aptima HPV E6/E7 mRNA test (P<0.05), and showed a higher efficacy for detection of normal tissues and chronic cervicitis (P<0.05) and low-grade squamous intraepithelial lesions (LSILs) (P<0.05) than Aptima HPV E6/E7 mRNA test; while Aptima HPV E6/E7 mRNA test showed a greater detection of high-grade squamous intraepithelial lesions (HSILs) (P<0.05) and invasive cervical carcinoma than HPV DNA test. Aptima HPV E6/E7 mRNA test exhibited a higher specificity P<0.05), positive and negative prediction rates than HPV DNA test for detection of cervical lesions, and the sensitivity was comparable between the two tests (P>0.05).

Conclusion: Aptima HPV E6/E7 mRNA test gradually improves the detection of cervical lesions with disease severity, and shows a higher specificity, positive and negative prediction rates and comparable sensitivity for detection of clinical cervical lesions as compared with HPV DNA test.

1. Cohen PA, Jhingran A, Oaknin A, Denny L (2019). Cervical cancer. Lancet, 393(10167): 169-82.
2. Arbyn M, Weiderpass E, Bruni L, et al (2020). Estimates of incidence and mor-tality of cervical cancer in 2018: a world-wide analysis. Lancet Glob Health, 8(2): e191-203.
3. Ali E, Kuelker R, Wassie B (2012). Under-standing cervical cancer in the context of developing countries. Ann Trop Med Public Health, 5(1): 3-15.
4. Beddoe AM (2019). Elimination of cervical cancer: challenges for developing coun-tries. Ecancermedicalscience, 13: 975.
5. Canfell K (2019). Towards the global elimi-nation of cervical cancer. Papillomavirus Res, 8: 100170.
6. Xia CF, Qiao YL, Zhang Y, Zhao FH (2020). WHO's global strategy of cervical cancer elimination and the challenges and initiatives in China. Zhonghua Yi Xue Za Zhi, 100(44): 3484-8.
7. Wang R, Pan W, Jin L, et al (2020). Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Lett, 471: 88-102.
8. Ibeanu OA (2011). Molecular pathogenesis of cervical cancer. Cancer Biol Ther, 11(3): 295-306.
9. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC (2013). Human papilloma-virus and cervical cancer. Lancet, 382(9895): 889-99.
10. Wardak S (2016). Human papillomavirus (HPV) and cervical cancer. Med Dosw Mikrobiol, 68(1): 73-84.
11. Li Y, Xu C (2017). Human papillomavirus-related cancers. Adv Exp Med Biol, 1018: 23-34.
12. Burk RD, Harari A, Chen Z (2013). Human papillomavirus genome variants. Virology, 445(1-2): 232-43.
13. Bhatla N, Singhal S (2020). Primary HPV screening for cervical cancer. Best Pract Res Clin Obstet Gynaecol, 65: 98-108.
14. Landy R, Castanon A, Hamilton W, et al (2016). Evaluating cytology for the detec-tion of invasive cervical cancer. Cytopathol-ogy, 27(3): 201-9.
15. Schiffman M, Kinney WK, Cheung LC, et al (2018). Relative performance of HPV and cytology components of cotesting in cer-vical screening. J Natl Cancer Inst, 110(5): 501-8.
16. Tsikouras P, Zervoudis S, Manav B, et al (2016). Cervical cancer: screening, diag-nosis and staging. J BUON, 21(2): 320-5.
17. Ratnam S, Coutlee F, Fontaine D, et al (2011). Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer. J Clin Microbiol, 49(2): 557-64.
18. Brisson M, Drolet M (2019). Global elimina-tion of cervical cancer as a public health problem. Lancet Oncol, 20(3): 319-21.
19. Kumar P, Gupta S, Das AM, Das BC (2019). Towards global elimination of cervical cancer in all groups of women. Lancet Oncol, 20(5): e237.
20. Hoppe-Seyler K, Bossler F, Braun JA, Herrmann AL, Hoppe-Seyler F (2018). The HPV E6/E7 oncogenes: Key factors for viral carcinogenesis and therapeutic targets. Trends Microbiol, 26(2): 158-68.
21. Rosty C, Sheffer M, Tsafrir D, et al (2005). Identification of a proliferation gene clus-ter associated with HPV E6/E7 expres-sion level and viral DNA load in invasive cervical carcinoma. Oncogene, 24(47): 7094-104.
22. McLaughlin-Drubin ME, Münger K (2009). Oncogenic activities of human papillo-maviruses. Virus Res, 143(2): 195-208.
Files
IssueVol 51 No 11 (2022) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v51i11.11172
Keywords
Cervical lesion Screening Human papillomavirus DNA Diagnostic performance
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Yang Z, Zhu W, Liu Y, Chen X. Performance of Aptima HPV E6/E7 mRNA Test for Detection of Cervical Lesions in a Large Chinese Population. Iran J Public Health. 2022;51(11):2549-2554.